Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Antibody–drug conjugates (ADCs) combine the targeting ability of monoclonal antibodies with the cell-killing effects of potent cytotoxic drugs. Over the past decade, the approach has moved from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results